| 发明名称 | Engineered CXCL12 alpha locked dimer polypeptide | ||
| 摘要 | The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS. | ||
| 申请公布号 | US9346871(B2) | 申请公布日期 | 2016.05.24 |
| 申请号 | US201313936650 | 申请日期 | 2013.07.08 |
| 申请人 | The Medical College of Wisconsin;The Rockefeller University | 发明人 | Volkman Brian F.;Veldkamp Christopher T.;Peterson Francis C.;Sakmar Thomas;Seibert Christoph H. |
| 分类号 | A61K38/16;C07K14/52;A61K38/00 | 主分类号 | A61K38/16 |
| 代理机构 | Quarles & Brady LLP | 代理人 | Quarles & Brady LLP |
| 主权项 | 1. A method of inhibiting HIV entry into CXCR4+ T cells in a subject comprising administering to the subject a composition comprising a CXCL12α2 locked dimer polypeptide in an amount effective to inhibit HIV entry into the CXCR4+ T cells, wherein the CXCL12α2 locked dimer polypeptide comprises two covalently linked CXCL12 monomers, each of which comprises the amino acid sequence of SEQ ID NO:1. | ||
| 地址 | Milwaukee WI US | ||